Tianjin Biosciences (IMAB, Financial) experienced significant stock movement with a sharp decline of 5.41%. The stock is currently priced at $1.05 per share with a trading volume of 313,029 shares, resulting in a turnover rate of 0.40% and a price fluctuation of 8.11%.
Recent financial reports indicate no recorded revenue for the company, with a net loss of $17.82 million and an earnings per share (EPS) of -$0.30. The company reported a gross profit of $0 and a price-to-earnings ratio of -0.96.
Despite the financial performance, analyst ratings are optimistic with all three participating institutions recommending a buy, while none advise holding or selling.
In the broader biotech sector, where IMAB is categorized, there has been an overall decline of 3.35%. Competing stocks like Revolution Medicines Inc and Tc Biopharm show significant gains, while Aditxt, Inc. and Evogene Ltd. are actively traded. Stocks with notable volatility include Vaccinex, Inc. and 180 Life Sciences Corp, with price swings reaching above 45%.
Tianjin Biosciences is a clinical-stage biotech firm focused on developing transformational biological treatments for immuno-oncology and immuno-inflammatory diseases. Their product lineup features Uliledlimab (TJD5), an antibody targeting solid tumors, among other innovative therapies.
